Skip to main content
Erschienen in: Archives of Osteoporosis 1/2016

01.12.2016 | Original Article

Utilization and cost of anti-osteoporosis therapy among US Medicare beneficiaries

verfasst von: Smita Jha, Timothy Bhattacharyya

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

There is a strong impetus to prevent and treat osteoporosis to prevent fractures. $990 million dollars was spent on anti-osteoporosis drugs in 2013. As we shift our focus on primary prevention of fractures, providers are encouraged to find the most cost-effective anti-osteoporosis therapy for patients.

Purpose

Osteoporosis is a major global problem with osteoporotic fractures posing a potentially avoidable burden on healthcare resources. We studied the utilization and cost of anti-osteoporotic therapy using the 2013 Medicare Part D data.

Methods

Descriptive data were produced from Microsoft Excel and SPSS regarding the anti-osteoporotic drugs of interest.

Results

In total, Medicare and its beneficiaries spent approximately $990 million on anti-osteoporotic therapy in 2013. Despite this cost, only one in two adults with osteoporosis aged 65 and older received a prescription for an anti-osteoporosis drug. $756 million (77 %) was attributable to brand name drugs which accounted for 2,459,931 claims (22 %). Generic dispensing rate varied from 57–86 % (mean 77 ± 6) across the different states in the USA. States that mandate substitution with generic equivalents had a higher generic dispensing rate compared to the states that permit generic substitution (92 vs. 90 %; p < 0.05). After adjusting for claim counts, we found that if the states that permit substitution with generic equivalents showed the same generic dispensing rate of 92 % as the states that mandate such substitution, there is a potential for savings of $7.5 million, approximately 9 % of the total expenditure in these states on oral bisphosphonates alone. Thirty-eight percent of the total prescriptions from orthopedic surgeons were for Forteo® or Prolia® compared to 12.5 % from specialists.

Conclusions

These findings highlight the need for ongoing training for physicians who engage in the care of patients with osteoporosis to manage the disease in a cost-effective manner.
Literatur
2.
Zurück zum Zitat Singer A et al. (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90(1):53–62CrossRefPubMed Singer A et al. (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90(1):53–62CrossRefPubMed
4.
Zurück zum Zitat Rianon N, Anand D, Rasu R (2013) Changing trends in osteoporosis care from specialty to primary care physicians. Curr Med Res Opin 29(8):881–888CrossRefPubMed Rianon N, Anand D, Rasu R (2013) Changing trends in osteoporosis care from specialty to primary care physicians. Curr Med Res Opin 29(8):881–888CrossRefPubMed
5.
Zurück zum Zitat Solomon DH et al. (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29(9):1929–1937CrossRefPubMedPubMedCentral Solomon DH et al. (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29(9):1929–1937CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bawa HS, Weick J, Dirschl DR (2015) Anti-osteoporotic therapy after fragility fracture lowers rate of subsequent fracture: analysis of a large population sample. J Bone Joint Surg Am 97(19):1555–1562CrossRefPubMed Bawa HS, Weick J, Dirschl DR (2015) Anti-osteoporotic therapy after fragility fracture lowers rate of subsequent fracture: analysis of a large population sample. J Bone Joint Surg Am 97(19):1555–1562CrossRefPubMed
7.
Zurück zum Zitat The Centers for Medicare and Medicaid Services (2015) Office of Enterprise Data and Analytics, Medicare Fee-For Service Provider Utilization & Payment Data Part D Prescriber Public Use File: A Methodological Overview The Centers for Medicare and Medicaid Services (2015) Office of Enterprise Data and Analytics, Medicare Fee-For Service Provider Utilization & Payment Data Part D Prescriber Public Use File: A Methodological Overview
8.
Zurück zum Zitat AARP Public Policy Institute (2009) The Medicare beneficiary population AARP Public Policy Institute (2009) The Medicare beneficiary population
9.
Zurück zum Zitat Centers for Medicare & Medicaid Services (2015) Medicare Fee-For Service Provider Utilization & Payment Data Part D Prescriber Public Use File, C.f.M.M. Services, Editor. Centers for Medicare & Medicaid Services: CMS.gov Centers for Medicare & Medicaid Services (2015) Medicare Fee-For Service Provider Utilization & Payment Data Part D Prescriber Public Use File, C.f.M.M. Services, Editor. Centers for Medicare & Medicaid Services: CMS.​gov
10.
Zurück zum Zitat Centers for Medicare & Medicaid Services (2015) CMS releases prescriber-level Medicare data for first time Centers for Medicare & Medicaid Services (2015) CMS releases prescriber-level Medicare data for first time
12.
Zurück zum Zitat Wright NC et al. (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29(11):2520–2526CrossRefPubMedPubMedCentral Wright NC et al. (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29(11):2520–2526CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Vlahiotis A et al. (2011) Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J Manag Care Pharm 17(2):123–132PubMed Vlahiotis A et al. (2011) Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J Manag Care Pharm 17(2):123–132PubMed
14.
Zurück zum Zitat Cummings SR et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–2082CrossRefPubMed Cummings SR et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–2082CrossRefPubMed
15.
Zurück zum Zitat Rosen CJ et al. (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20(1):141–151CrossRefPubMed Rosen CJ et al. (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20(1):141–151CrossRefPubMed
16.
Zurück zum Zitat Bonnick S et al. (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91(7):2631–2637CrossRefPubMed Bonnick S et al. (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91(7):2631–2637CrossRefPubMed
17.
Zurück zum Zitat Chesnut CH III et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19(8):1241–1249CrossRefPubMed Chesnut CH III et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19(8):1241–1249CrossRefPubMed
19.
Zurück zum Zitat Haas J (2005) P.K., Gerstenberger E, Segar A, Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 142(11):891–897CrossRefPubMed Haas J (2005) P.K., Gerstenberger E, Segar A, Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 142(11):891–897CrossRefPubMed
20.
Zurück zum Zitat Nightingale S (1987) M.J., Generic drugs and the prescribing physician. Journal of American Medical Association 258(9):1200–1204CrossRef Nightingale S (1987) M.J., Generic drugs and the prescribing physician. Journal of American Medical Association 258(9):1200–1204CrossRef
21.
Zurück zum Zitat Steinman MA, Chren MM, Landefeld CS (2007) What's in a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med 22(5):645–648CrossRefPubMedPubMedCentral Steinman MA, Chren MM, Landefeld CS (2007) What's in a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med 22(5):645–648CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Shrank WH et al. (2011) Physician perceptions about generic drugs. Ann Pharmacother 45(1):31–38CrossRefPubMed Shrank WH et al. (2011) Physician perceptions about generic drugs. Ann Pharmacother 45(1):31–38CrossRefPubMed
23.
Zurück zum Zitat Gu Q et al. (2009) Part D coverage gap and adherence to diabetes medications. Am J Manag Care 16(12):911–918 Gu Q et al. (2009) Part D coverage gap and adherence to diabetes medications. Am J Manag Care 16(12):911–918
24.
Zurück zum Zitat Shrank WH et al. (2006) The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 166(3):332–337CrossRefPubMed Shrank WH et al. (2006) The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 166(3):332–337CrossRefPubMed
25.
Zurück zum Zitat Kanis J et al. (2012) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 23(1):213–221CrossRefPubMed Kanis J et al. (2012) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 23(1):213–221CrossRefPubMed
26.
Zurück zum Zitat Lai PSM et al. (2012) The effect of mandatory generic substitution on the safety of alendronate and patients’ adherence. Curr Med Res Opin 28(8):1347–1355CrossRefPubMed Lai PSM et al. (2012) The effect of mandatory generic substitution on the safety of alendronate and patients’ adherence. Curr Med Res Opin 28(8):1347–1355CrossRefPubMed
27.
Zurück zum Zitat Sheehy O et al. (2009) Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 20(8):1369–1376CrossRefPubMed Sheehy O et al. (2009) Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 20(8):1369–1376CrossRefPubMed
28.
Zurück zum Zitat Ström O, Landfeldt E (2012) The association between automatic generic substitution and treatment persistence with oral bisphosphonates. Osteoporos Int 23(8):2201–2209CrossRefPubMed Ström O, Landfeldt E (2012) The association between automatic generic substitution and treatment persistence with oral bisphosphonates. Osteoporos Int 23(8):2201–2209CrossRefPubMed
29.
Zurück zum Zitat Centers for Disease Control and Prevention (2015) Strategies used by adults to reuse their prescription drug costs: United States, 2013, U.S.D.o.H.a.H. Services, Editor. January Centers for Disease Control and Prevention (2015) Strategies used by adults to reuse their prescription drug costs: United States, 2013, U.S.D.o.H.a.H. Services, Editor. January
30.
Zurück zum Zitat Alberto J, Espay M, et al. (2015) Placebo effect of medication cost in Parkinson disease. Neurology 84:1–9CrossRef Alberto J, Espay M, et al. (2015) Placebo effect of medication cost in Parkinson disease. Neurology 84:1–9CrossRef
31.
Zurück zum Zitat Dreinhofer KE et al. (2005) Multinational survey of osteoporotic fracture management. Osteoporos Int 16(Suppl 2):S44–S53CrossRefPubMed Dreinhofer KE et al. (2005) Multinational survey of osteoporotic fracture management. Osteoporos Int 16(Suppl 2):S44–S53CrossRefPubMed
32.
Zurück zum Zitat Federman AD, Halm EA, Siu AL (2007) Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care. Med Care 45(2):109–115CrossRefPubMed Federman AD, Halm EA, Siu AL (2007) Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care. Med Care 45(2):109–115CrossRefPubMed
33.
34.
Zurück zum Zitat Ettinger B et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645CrossRefPubMed Ettinger B et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645CrossRefPubMed
35.
Zurück zum Zitat Sambrook PN et al. (2004) Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 255(4):503–511CrossRefPubMed Sambrook PN et al. (2004) Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 255(4):503–511CrossRefPubMed
36.
Zurück zum Zitat Whitaker M et al. (2012) Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366(22):2048–2051CrossRefPubMed Whitaker M et al. (2012) Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366(22):2048–2051CrossRefPubMed
37.
Zurück zum Zitat Laliberte MC et al. (2010) Impact of a primary care physician workshop on osteoporosis medical practices. Osteoporos Int 21(9):1471–1485CrossRefPubMed Laliberte MC et al. (2010) Impact of a primary care physician workshop on osteoporosis medical practices. Osteoporos Int 21(9):1471–1485CrossRefPubMed
Metadaten
Titel
Utilization and cost of anti-osteoporosis therapy among US Medicare beneficiaries
verfasst von
Smita Jha
Timothy Bhattacharyya
Publikationsdatum
01.12.2016
Verlag
Springer London
Erschienen in
Archives of Osteoporosis / Ausgabe 1/2016
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-016-0283-2

Weitere Artikel der Ausgabe 1/2016

Archives of Osteoporosis 1/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.